Dietary genistein inhibits metastasis of human prostate cancer in mice

Cancer Research

Volumn 68, Issue 6, 2008, Pages 2024-2032

  Lakshman, Minalini ^a   Xu, Li ^a   Ananthanarayanan, Vijayalakshmi ^a   Cooper, Joshua ^b   Takimoto, Chris H ^b   Helenowski, Irene ^a   Pelling, Jill C ^a   Bergan, Raymond C ^a,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CTRC Institute for Drug Development   (United States)

^c Olson 8321 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE; GENISTEIN; HEAT SHOCK PROTEIN 27; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL ADHESION; CELL INVASION; CONTROLLED STUDY; DIETARY INTAKE; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LUNG METASTASIS; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GROWTH;

ANIMALS; ANTICARCINOGENIC AGENTS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DIET; ENZYME ACTIVATION; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GENISTEIN; HEAT-SHOCK PROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MICE; NEOPLASM PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROSTATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 40949129259     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1246     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Carroll PR, Lee KL, Fuks ZY, Kantoff PW. Cancer of the Prostate. In: DeVita VT, Hellman S, Rosenberg SA, editors. CANCER: Principals and Practices of Oncology. New York: Lippincott-Raven; 2001. p. 1418-79.
3. Ruoslahti E. How cancer spreads. Sci Am 1996;275:72-7.
4. Stetler-Stevenson WG, Yu AE. Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol 2001;11:143-52.
5. Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis. Cancer 1997;80:1529-37.
6. Bergan R, Kyle E, Nguyen P, Trepel J, Ingui C, Neckers L. Genistein-stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to β-1-integrin. Clin Exp Metastasis 1996;14:389-98.
7. Liu YU, Kyle E, Lieberman R, Crowell J, Kelloff G, Bergan RC. Focal adhesion kinase (FAK) phosphorylation is not required for genistein-induced FAK-b-1-integrin complex formation. Clin Exp Metastasis 2000;18:203-12.
8. Huang X, Chen S, Xu L, et al. Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res 2005;65:3470-8.
9. Xu L, Bergan RC. Genistein inhibits MMP-2 activation and prostate cancer cell invasion by blocking TGF{β}-mediated activation of MAPKAPK2-27 pathway. Mol Pharmacol 2006;70:869-77.
10. Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB, Parsons JT. pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci U S A 1992;89:5192-6.
11. Hanks SK, Calalb MB, Harper MC, Patel SK. Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin. Proc Natl Acad Sci U S A 1992;89:8487-91.
12. Cobb BS, Schaller MD, Leu TH, Parsons JT. Stable association of pp60src and pp59fyn with the focal adhesion-associated protein tyrosine kinase, pp125FAK. Mol Cell Biol 1994;14:147-55.
13. Liu YQ, Kyle E, Patel S, et al. Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells. Prostate Cancer Prostatic Dis 2001;4:81-91.
14. Tremblay L, Hauck W, Aprikian AG, Begin LR, Chapdelaine A, Chevalier S. Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma. Int J Cancer 1996;68:164-71.
15. Kyle E, Neckers L, Takimoto C, Curt G, Bergan R. Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Mol Pharmacol 1997;51:193-200.
16. Xu L, Chen S, Bergan RC. MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. Oncogene 2006;25:2987-98.
17. Hayes SA, Huang X, Kambhampati S, Platanias LC, Bergan RC. p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion. Oncogene 2003;22:4841-50.
18. Liu Y, Jovanovic B, Pins M, Lee C, Bergan RC. Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion. Oncogene 2002;21:8272-81.
19. Craft CS, Romero D, Vary CPH, Bergan RC. Endoglin inhibits prostate cancer motility via activation of the ALK2-1 pathway. Oncogene 2007;26:7240-50.
20. Craft CS, Xu L, Romero D, Vary CPH, Bergan RC. Genistein induces phenotypic reversion of endoglin deficiency in human prostate cancer cells. Mol Pharmacol 2008;73:235-42.
21. Rocchi P, Beraldi E, Ettinger S, et al. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res 2005;65:11083-93.
22. Rocchi P, So A, Kojima S, et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004;64:6595-602.
23. Cornford PA, Dodson AR, Parsons KF, et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 2000;60:7099-105.
24. Messina MJ, Persky V, Setchell KD, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994;21:113-31.
25. Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 1993;342:1209-10.
26. Adlercreutz H. Western diet and Western diseases: some hormonal and biochemical mechanisms and assocaitions. Scand J Clin Lab Invest 1990;50 Suppl 201:3-23.
27. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991;63:963-6.
28. Severson RK, Nomura AM, Grove JS, Stemmermann GN. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res 1989;49:1857-60.
29. Cook LS, Goldoft M, Schwartz SM, Weiss NS. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol 1999;161:152-5.
30. Simpson L, He X, Pins M, et al. Renal medullary carcinoma and ABL gene amplification. J. Urology 2005;173:1883-8.
31. Bergan R, Hakim F, Schwartz GN, et al. Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging. Blood 1996;88:731-41.
32. Takimoto CH, Glover K, Huang X, et al. Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol Biomarkers Prev 2003;12:1213-21.
33. Kelley MJ, Glaser EM, Herdon JE, et al. Safety and efficacy of weekly oral oltipraz in chronic smokers. Cancer Epidemiol Biomarkers Prev 2005;14:892-9.
34. Venkataraman G, Ananthanarayanan V, Paner GP, et al. Morphometric sum optical density as a surrogate marker for ploidy status in prostate cancer: an analysis in 180 biopsies using logistic regression and binary recursive partitioning. Virchows Arch 2006;449:302-7.
35. Bacus JW, Boone CW, Bacus JV, et al. Image morphometric nuclear grading of intraepithelial neoplastic lesions with applications to cancer chemoprevention trials. Cancer Epidemiol Biomarkers Prev 1999;8:1087-94.
36. Lakshman M, Subramaniam V, Jothy S. CD44 negatively regulates apoptosis in murine colonic epithelium via the mitochondrial pathway. Exp Mol Pathol 2004;76:196-204.
37. Lakshman M, Subramaniam V, Wong S, Jothy S. CD44 promotes resistance to apoptosis in murine colonic epithelium. J Cell Physiol 2005;203:583-8.
38. Uzgare AR, Isaacs JT. Prostate cancer: potential targets of anti-proliferative and apoptotic signaling pathways. Int J Biochem Cell Biol 2005;37:707-14.
39. Humphries MJ. Cell adhesion assays. Mol Biotechnol 2001;18:57-61.
40. Bartels PH, Montironi RM, Bostwick D, et al. Karyometry of secretory cell nuclei in high-grade PIN lesions. Prostate 2001;48:144-55.
41. Veltri RW, Partin AW, Miller MC. Quantitative nuclear grade (QNG): a new image analysis-based biomarker of clinically relevant nuclear structure alterations. J Cell Biochem 2000;Suppl 35:151-7.
42. Fischer L, Mahoney C, Jeffcoat AR, et al. Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia. Nutr Cancer 2004;48:160-70.
43. Clinical development plan: genistein. J Cell Biochem Suppl 1996;26:114-126.
44. Nabhan C, Bergan R. Chemoprevention in prostate cancer. In: Bergan RC, editor. Cancer Chemoprevention. Boston: Kluwer Academic Publishers; 2001. p. 103-36.
45. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003;3:453-8.
46. Kosmeder JW, Pezzuto JM. Intermediate Biomarkers. In: Bergan RC, editors. Cancer Chemoprevention. Boston: Kluwer Academic Publishers; 2001. p. 31-62.
47. Matsumura A, Ghosh A, Pope GS, Darbre PD. Comparative study of oestrogenic properties of eight phytoestrogens in MCF7 human breast cancer cells. J Steroid Biochem Mol Biol 2005;94:431-43.
48. Wang Y, Raffoul JJ, Che M, et al. Prostate cancer treatment is enhanced by genistein in vitro and in vivo in a syngeneic orthotopic tumor model. Radiat Res 2006;166:73-80.
49. Ding Y, Xu L, Chen S, et al. Characterization of a method for profiling gene expression in cells recovered from intact human prostate tissue using RNA linear amplification. Prostate Cancer Prostatic Dis 2006;9:379-91.
50. Schwartz GN, Liu YQ, Tisdale J, et al. Growth inhibition of chronic myelogenous leukemia cells by ODN-1, an aptameric inhibitor of p210bcr-abl tyrosine kinase activity. Antisense Nucleic Acid Drug Dev 1998;8:329-39.